CogState releases details of UBC agreement

By Dylan Bushell-Embling
Tuesday, 29 July, 2008

Melbourne's CogState [ASX: CGS] has released the terms of its planned partnership with US pharmaceutical services company United BioSource Corporation [UBC], announced last week.

Under the arrangement, CogState and UBC will join forces to provide a comprehensive cognitive testing solution for use in clinical trials.

CogState markets six computerised diagnostic products to test cognitive function. It also has a therapeutic division with two compounds in early develop for Alzheimer's and Parkinson's diseases.

Under the agreement, UBC will buy a 15 per cent share in CogState, at a cost of around $800,000. UBC will also underwrite CogState's share rights issue.

Both companies will remain separate entities. In a statement to the stock exchange, CogState stressed that the arrangement will not necessitate any management changes or job losses.

Related News

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd